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Abstract Receptors for insulin and insulin-like growth factor-I
(IR and IGFIR) consisting of the K2L2 structure are protein
tyrosine kinases (PTKs). Carboxyl-terminal (CT) domains of
their L subunits are structurally diverse while the PTK domains
share the highest homology. Interactions between CT and PTK
domains of IR and IGFIR were studied by means of PTK
activity, fluorescence energy transfer or surface plasmon
resonance using BIAcore. We present evidence that IGFIR CT
directly interacts with both IGFIR and IR. Although binding to
both receptors, stimulation of PTK activity only occurs with IR
but not IGFIR.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The insulin-like growth factor-I receptor (IGFIR) and the
insulin receptor (IR) are biologically active macromolecules
which are responsible for transducing signals of IGF-I and
insulin, respectively [1,2]. Both receptors are tetrameric mem-
brane glycoproteins consisting of two K and two L subunits
which are disul¢de-linked in a L-K-K-L form. The initial event
of IGF-I and insulin action is binding to the extracellular K
subunits of IGFIR or IR. This interaction activates the intra-
cellular protein tyrosine kinase (PTK) activity of the receptor
L subunit by conformational changes and autophosphoryla-
tion, and initiates post-receptor signal transduction in the cell
that leads to changes in growth and metabolism.
The crystal structure of the IR PTK reported by Hubbard
et al. [3] has provided information on the 3D structure of the
IR PTK, yet some important structural elements are lacking.
The crystal structure of IR PTK contained 306 amino acid
residues and lacked the carboxyl-terminal (CT) 72 amino
acids of the L subunit as well as 25 amino acids of the juxta-
membrane domain. Although the overall homology of human
IGFIR and IR CT domains is 44% [4], their structural fea-
tures are signi¢cantly di¡erent. IGFIR CT and IR CT consist
of 108 and 99 amino acids, respectively. IGFIR CT contains
an unusually high content of Pro (12 mol%) and 3 Tyr resi-
dues while IR CT contains 7 Pro (7 mol%) and 2 Tyr residues.
The di¡erent sequences in the CT domains suggest potential
di¡erences in their e¡ects on PTK activity as well as signaling
pathways that are utilized by the two receptors.
The potential involvement of the CT domains in di¡erential
signal transductions for insulin and IGFs has been proposed
[5^12]. Initially, a number of studies used CT domain deletion
mutants of IR [5^9]. While these results are somewhat con-
troversial, studies utilizing cells expressing chimeric receptors
provided more convincing information [10^12]. For example,
insulin failed to stimulate pyruvate dehydrogenase (PDH) ac-
tivity in cells expressing IR carrying IGFIR CT110 amino
acids [10]. Replacement of IR CT with IGFIR CT in the IR
severely a¡ected insulin-stimulated responses [11]. In cells ex-
pressing a chimeric IGFIR having IR CT, stimulation of gly-
cogen synthesis or mitogen-associated protein (MAP) kinase
by IGF-I was similar to the level achieved by insulin-stimu-
lated IR [12]. These data suggested that the CT domains of IR
and IGFIR are not reciprocally interchangeable.
Amino- and carboxyl-terminal regions of many proteins are
often highly susceptible to proteolytic digestion. Previously,
we showed that the removal of the CT domain 76 amino acids
from IR PTK resulted in much lower PTK activity and en-
hanced susceptibility to heat inactivation and proteolytic deg-
radation than the intact IR PTK [13]. IR CT stimulated both
the intact and CT-truncated forms of IR PTK 2.7- and 2.5-
fold, respectively [14]. These results indicate that IR CT plays
an important role in the activity and stability of IR PTK.
Towards understanding the structure and function of the
IGFIR CT, IGFIR CT was puri¢ed from a glutatione S-
transferase (GST) fusion protein. In addition, we expressed
and puri¢ed (His)6-tag IR CT as well as (His)6-tag IGFIR
CT, and investigated whether CT domains of IGFIR and
IR can interact with PTK domains of IR and IGFIR. We
present evidence that IGFIR CT directly interacts with the
PTK domains of both IGFIR and IR, leading to activation
of IR PTK without signi¢cantly a¡ecting the IGFIR PTK
activity.
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2. Materials and methods
2.1. Expression and puri¢cation of the IGFIR CT
A DNA fragment corresponding to the CT domain (residues 1231^
1337) [4] of IGFIR was ampli¢ed by PCR using 3P- and 5P-primers
containing EcoRI or BamHI restriction enzyme sites, respectively, to
permit directional cloning. After digestion with restriction enzymes,
the PCR product was inserted into the pGEX3X expression vector
(Pharmacia), which allowed production of the inserted polypeptide as
a fusion protein with GST. Escherichia coli strain JM109 was trans-
formed with the plasmid, and the expression of the GST-CT fusion
protein was con¢rmed by SDS-PAGE. IGFIR CT was then puri¢ed
from overnight cultures of E. coli JM109/pGEX3X CT by the same
method previously described [14] except that 30 Wg of the restriction
protease factor Xa (Boehringer Mannheim, Indianapolis, IN) (en-
zyme/substrate ratio of V1/100) was used for elution of the CT do-
main. Puri¢ed IGFIR CT was analyzed by SDS-PAGE, immunoblot-
ting, amino acid composition, and 1D NMR.
2.2. Expression and puri¢cation of IGFIR CT and IR CT with
(His)6 -tag
Overnight cultures (100 ml NZY medium) of E. coli DH52 trans-
formed with pTrcHisB/IGFIR 1229^1337 [4] or pTrc/HisB/IR 1245^
1330 [15] were diluted 10 times into 1 liter of fresh LB medium. E. coli
DH52 transformants were grown for 1 h, and an additional 3 h at
37‡C after the addition of isopropylthio-L-D-galactosine (IPTG) (0.1
and 1 mM, respectively), and harvested by centrifugation at 3000 rpm
for 10 min at 4‡C. Bacteria were then homogenized in 20 mM sodium
phosphate, pH 7.8, containing 6 M guanidine-HCl and 0.5 M NaCl at
25‡C for 10 min, followed by sonication 3 times for 5 s. The homog-
enates from 100 ml culture were applied onto a Ni2-N-(5-amino-1-
carboxypentyl)-iminodiacetic acid (NTA)-agarose column (1 ml; Qia-
gen, Valencia, CA). The column was washed with 20 mM sodium
phosphate, pH 6.0, containing 8 M urea and 0.5 M NaCl until all
proteins were eluted as judged by A2806 0.01, and then eluted with
20 mM sodium phosphate, pH 4.0, containing 8 M urea and 0.5 M
NaCl. Puri¢ed (His)6-tag IGFIR CT and (His)6-tag IR CT were used
only for BIAcore experiment 3.
2.3. Fluorescence labeling of IGFIR CT and measurement of emission
spectra in the presence of increasing amounts of IR PTK
Puri¢ed IGFIR CT was labeled with E-99 (eosin-5-iodoacetamide,
Molecular Probes, Eugene, OR) at the unique Cys residue located at
the C-terminus. IGFIR CT (V200 Wg) in 0.9 ml of 0.5 M potassium
phosphate, pH 8.0, containing 1 mM DTT and 18 mM 3-[(3-chol-
amidopropyl)dimethylammonio]-1-propane sulfonate (CHAPS) was
mixed with 100 Wl of 16 mM E-99 dissolved in N,N-dimethyl form-
amide (DMF). Reaction was allowed to continue for 16 h at 4‡C, and
stopped by dialyzing against 50 mM Tris-HCl, pH 7.4, containing
1 mM DTT at 4‡C. To further remove unreacted dye, the dialysate
was applied to a Sephadex G-50 column (20 ml) equilibrated with 50
mM Tris-HCl, pH 7.4, containing 1 mM DTT and 0.15 M NaCl at
4‡C. The eluates were monitored by absorbance at 280 and 540 nm.
Fractions with A280=540 =V6 were combined. The labeled IGFIR CT
(V3 WM) in 500 Wl was titrated with puri¢ed and concentrated Triton
X-100-free IR PTK or BSA by successively adding 1, 4, 5, 10, and
15 Wl of each protein solution (V2 Wg/100 Wl). The emission spectra
were recorded at 5 min after the addition of IR PTK or BSA by
exciting the sample at 305 nM with a Hitachi F-2000 £uorescence
spectrometer (Hitachi, Tokyo, Japan).
2.4. Measurement of binding interaction by surface plasmon resonance
For experiments 1 and 3, IR puri¢ed from Rat1HIR cells was
immobilized using BIAcore Amine Coupling Kit (Biacore, Piscat-
away, NJ) with 10 mM sodium acetate, pH 5 [16]. Brie£y, sensor
chips were activated by 50 mM N-hydroxysuccimide (NHS)/200
mM N-ethyl-NP-(3-diethylaminopropyl)-carbodiimide (EDC), coupled
with IR (30 Wl of 50 Wg/ml), and then blocked by ethanol amine-HCl.
To the IR-immobilized chips, analytes such as IGFIR CT (50 or
150 Wg/ml), insulin (100 Wg/ml), BSA (50 Wg/ml), (His)6-tag IGFIR
CT and (His)6-tag IR CT (50 or 150 Wg/ml) were applied and sensor-
grams recorded. For experiment 2, IGFIR CT was immobilized on a
sensor chip by thiol-disul¢de exchange at the unique C-terminal cys-
teine residue. Brie£y, the chip was activated by NHS/EDC as above,
and reactive disul¢de groups were introduced onto the sensor chip
surface by reaction with 80 mM 2-(2-pyridinyldithio)ethaneamine hy-
drochloride (PDEA) in 100 mM borate bu¡er, pH 8.5. The chip was
then coupled with IGFIR CT (400 Wg/ml in 10 mM sodium formate,
pH 3.8), and blocked by 50 mM L-cysteine/1 M NaCl deactivating
solution. To this chip, IR PTK (10 Wg/ml), IR (50 Wg/ml), insulin
(50 Wg/ml), and IGFIR PTK (5 Wg/ml) were applied and sensorgrams
recorded.
2.5. Other methods
IR PTK, IR PTKvCT, and IGFIR PTK were expressed in insect
cells and puri¢ed as previously described [5,6]. IR was puri¢ed from
Triton X-100 solubilized Rat1HIR cells by sequential a⁄nity chroma-
tography on wheat germ agglutinin (WGA)- and insulin-Sepharose as
described [17]. SDS-PAGE and immunoblotting were performed using
15% polyacrylamide gels as described [18]. PTK activity was measured
using a poly(Glu,Tyr)(4:1) substrate as described [19].
3. Results
3.1. Puri¢cation of CT domains
Approximately 1 mg of IGFIR CT was puri¢ed by gluta-
thione-Sepharose chromatography from a 1 liter culture. This
IGFIR CT preparation was used for £uorescent-labeling and
BIAcore experiments. For determination of the e¡ect of
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Table 1
E¡ects of IR CT and IGFIR CT on IR or IGFIR PTK activity
Fold stimulation over basal
IGFIR CT IR CTa BSA
IGFIR PTK 0.83 þ 0.24 (Ps 0.1, n = 8) 1.2 þ 0.3 (Ps 0.1, n = 11) 1.03 þ 0.05 (n = 3)
IR PTK 1.8 þ 0.6 (P6 0.05, n = 6) 2.7 þ 1.0 (P6 0.01, n = 7) 0.98 þ 0.02 (n = 4)
IR PTKvCT 3.7 þ 1.3 (P = 0.1, n = 3) 2.5 þ 0.4 (P6 0.05, n = 3) 0.92 þ 0.09 (n=2)
aThe e¡ects of IR CT on IGFIR PTK, IR PTK, and IR PTKvCT have been published previously [6]. For the former two PTKs, however,
additional PTK assays from this study are included.
Fig. 1. Emission spectra of the eosin-labeled IGFIR CT in the pres-
ence of varying amounts of IR PTK (F) or BSA (E). Emission spec-
tra were recorded each time 5 min after the £urescence-labeled
IGFIR CT was mixed with indicated amounts of IR PTK or BSA
(V2 Wg/100 Wl). Relative £uorescence intensity changes at 540 nm
are shown.
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IGFIR CT on PTK activity, it was further puri¢ed by Mono
Q chromatography. (His)6-tag IGFIR CT and (His)6-tag IR
CT, 360 and 320 Wg, respectively, were puri¢ed by Ni2-NTA-
agarose chromatography from 33 ml culture. All the puri¢ed
CT domains were apparently pure as judged by SDS-PAGE
and immunoblotting. IGFIR CT isolated from its GST fusion
protein contained Gly-Ile at the N-terminal CT domain
(1230^1337) due to the introduction of the BamHI site for
cloning. (His)6-tag IGFIR CT contained 158 amino acids con-
sisting of IGFIR CT (109 amino acids), (His)6 and a restric-
tion protease processing site at the N-terminus, and 16 amino
acids at the C-terminus. (His)6-tag IR CT contained 135 ami-
no acids consisting of IR CT (86 amino acids) and other
residues similar to the (His)6-tag IGFIR CT construct. The
(His)6-tag IR CT lacked C-terminal 13 amino acids of the IR
CT.
3.2. E¡ect of IGFIR CT on PTK activity
The e¡ect of IGFIR CT on both IR and IGFIR PTK
activities was examined together with the e¡ect of IR CT.
All the results are expressed as fold stimulation of the max-
imal e¡ect within the tested range (Table 1). Both IGFIR CT
and IR CT stimulated IR PTK and IR PTKvCT. In contrast,
IGFIR CT and IR CT showed slight inhibitory and stimula-
tory e¡ects on IGFIR PTK, respectively. The observed e¡ects
of all tested CT domains on IGFIR PTK were, however,
highly variable, and not statistically signi¢cant (Ps 0.1).
3.3. Measurement of the interaction between the IGFIR CT
and IR PTK
The puri¢ed £uorescence-labeled IGFIR CT was titrated
with IR PTK or BSA. The emission spectra relative intensity
increased after addition of increasing amounts of IR PTK
(V0.6^20 nM). No increase in the emission spectra was
seen when BSA was added. The changes in emission spectra
observed at 540 nm after the addition of IR PTK are shown
FEBS 19671 8-1-98
Table 2
Interactions of CT domains of IGFIR and IR L subunits with their PTKs as measured by surface plasmon resonance: summary of BIAcore
experiments
A. Experiment 1
Ligand on the chip IR RU (+2495)
Analyte 1 BSA 0
Analytes 2, 3, and 4 IGFIR CT 7.3 þ 1.2
Analyte 5 Insulin 21
B. Experiment 2
Ligand on the chip IGFIR CT RU (+791)
Analyte 1 IR PTK 51
Analyte 2 IR 16
Analyte 3 Insulin 0
Analyte 4 IGFIR PTK 82
C. Experiment 3
Ligand on the chip IR RU (+1492)
Analytes 1 and 2 IGFIR CT 4.5 þ 1.5
Analytes 3 and 4 (His)6-tag IGFIR CT 18.5 þ 3.5
Analytes 5 and 6 (His)6-tag IR CT 12 þ 3
Analyte 7 BSA 33
Analyte 8 Insulin 50
Analyte proteins were successively passed though the sensor chips instead of washing the bound analyte o¡ each time. This procedure appeared to
be acceptable since even after all the analytes were passed through, only 0.8%, 17%, and 5% of the total available binding sites of immobilized
proteins on the chips, for experiments 1, 2, and 3, respectively, were occupied. Increases in RU after the coupling of ligand on the chip are shown in
parentheses, 2495, 791, and 1492 for experiments 1, 2, and 3, respectively.
Fig. 2. Schematic presentation of a hypothesis for the structure-
function relationship between IR PTK and its CT domain. A and B
forms represent CT-bound and CT-open IR PTK, that are in equili-
brium. Binding of insulin to the extracellular domain should shift
the equilibrium, BCA, whereas Ser/Thr phosphorylation probably
shift the equilibrium, ACB. The B form is very susceptible to pro-
teases, and easily degraded to an inactive C form. Both B and C
forms can be activated by binding of exogenously added CT do-
mains (IR CT and IGFIR CT) to the IR PTK domain, BCE and
CCD. Note that ‘inactive’ means very low PTK activity such as
6 10% PTK activity of the active form. AP and DP show constitu-
tively activated IR PTK by autophosphorylation whereas A, D, and
E are transient forms required for the autophosphorylation reaction.
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in Fig. 1. In this particular experiment, up to 12.4% increase
in the relative £uorescence intensity at 540 nm was observed.
In another experiment, an increase in the relative intensity was
15.9% of the £uorescence intensity measured in the absence of
IR PTK. These changes are apparently induced as a result of
the IGFIR CT speci¢cally interacting with IR PTK domain.
Kd values of 5 and 3.2 nM were obtained from two independ-
ent experiments.
3.4. BIAcore experiments
As a more direct method for detecting binding interactions
between CT and PTK domains, we used a surface plasmon
resonance detector (BIAcore). The results of BIAcore experi-
ments are summarized in Table 2. In experiment 1, puri¢ed IR
was immobilized to the sensor chip. A resonance unit (RU)
increase of 2495 was detected. Analytes as listed were then
successively applied. The di¡erence in RU values before and
after the addition of an analyte, which indicates a binding
interaction, was measured for each analyte. The results, sum-
marized in Table 2A, indicate that control BSA does not bind
to IR whereas IGFIR CT and insulin both bind to IR. The
RU values observed with IGFIR CT were consistently lower
than that of insulin, suggesting low a⁄nity and/or fast disso-
ciation of the interaction between IGFIR CT and IR PTK. In
experiment 2, IGFIR CT was immobilized on the chip, and
analytes such as IR PTK and IGFIR PTK were passed
through. The results show that IR PTK as well as IGFIR
PTK bound to IGFIR CT whereas insulin did not bind to
it (Table 2B). These results suggest that IGFIR CT binds to
both IGFIR and IR PTKs. Experiment 3 was carried out to
further con¢rm our observation that IGFIR CT binds to IR
PTK, and also to examine whether IR CT binds to IR PTK.
IGFIR CT, (His)6-tag IGFIR CT, and (His)6-tag IR CT were
passed over the IR-immobilized chip. The results, shown in
Table 2C, not only con¢rmed that IGFIR CT binds to IR,
but also indicated that IR CT binds to IR. Positive and neg-
ative controls, insulin and BSA, yielded the expected results.
Therefore, BIAcore experiments provided direct evidence that
IGFIR CT binds to IR PTK as well as IGFIR PTK, and that
IR CT binds to IR PTK as well.
4. Discussion
Our previous and present studies suggest that CT domains
of IR and IGFIR modulate PTK activity di¡erently. When
the CT domains are exogenously added, IR CT stimulates IR
PTK activity, but IGFIR CT does not appear to stimulate
IGFIR PTK activity even though the binding interactions
between IGFIR CT and PTK domains can be detected by
BIAcore. IGFIR PTK was not signi¢cantly activated by IR
CT, either. Interestingly, however, IGFIR CT stimulates IR
PTK activity. BIAcore experiments suggest that IR PTK
binds IR CT as well as IGFIR CT. Thus, it is most likely
that the binding of the CT domains to the IR PTK domain
results in stimulation of IR PTK activity. In contrast, IGFIR
PTK activity does not appear to be a¡ected signi¢cantly by
either IGFIR CT or IR CT. In summary, stimulation of
IGFIR PTK activity is distinct from that of IR PTK, and is
una¡ected by CT domains, suggesting a di¡erent mechanism
for modulation of PTK activity.
IR and IR PTK contain an intact CT domain whereas IR
PTKvCT lacks the IR CT consisting of 76 amino acids [13]. It
is of interest to note that both IR PTK with and without CT
were activated by exogenously added IR CT or IGFIR CT,
and that both IR PTKs with or without CT bind to the CT
domains exogenously added. If the IR CT domain is tightly
associated with the IR PTK domain in an intact IR molecule,
IR PTK containing the CT domain should not bind exoge-
nously added CT domains. The results of this study thus
suggest that the IR CT domain in the IR molecule must be
mobile as illustrated in Fig. 2A and B, CT-bound and CT-
open forms, respectively, which exist in equilibrium. Only
when IR PTK is in the B form (CT-open form), an exoge-
nously added IR CT or IGFIR CT can directly interact with
IR PTK domain (Fig. 2BCE). The CT domain has a £exible
structure, which is most likely to cause susceptibility to pro-
teolysis (Fig. 2BCC). We showed earlier that the L subunit of
IR is extremely susceptible to proteolysis [20]. Consistent with
this observation, the 3D structure of IR PTK published did
not include the C-terminal 72 amino acids since the N and C
termini of the crystallized IR PTK were chosen on the basis of
proteolytic studies performed on the entire cytoplasmic do-
main of the L subunit [3].
Previously, we showed that the deletion of the C-terminal
76 amino acids from IR PTK impairs catalytic e⁄ciency and
stability of IR PTK, and suggested that the IR CT domain
plays an important role in the activation and stabilization of
IR PTK [13]. PTK activity of this CT-truncated form of IR
PTK, as illustrated in Fig. 2C, was reduced to V10% of the
intact IR PTK. This form can be activated by exogenously
added CT domains (Fig. 2CCDCDP). The CT-open form
can be activated by insulin (Fig. 2BCACAP) or by exoge-
nously added CT domains (Fig. 2BCECAP). This model
thus predicts that if exogenously added CT domains bind to
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Fig. 3. Schematic presentation of a possible interaction of IGFIR CT with IR TPK in cell. Cytoplasmic domains of an intact IGFIR with its
CT domain and an inactive IR without its CT domain are depicted (open and shaded, respectively). When IGFIR and IR hybrids are formed,
IGFIR CT may be able to interact with the IR PTK domain, resulting in the activation of the IR PTK.
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the PTK domain, partially inactive IR PTKs, the B and C
forms, can be stimulated to an activity approaching that of
the A form.
This model also predicts that insulin binding to the extra-
cellular domain may cause a conformational change in the CT
domain and therefore shift the equilibrium from B to A form.
This accounts for the activation of IR PTK (Fig. 2ACAP).
Consistent with this, Baron et al. suggested that insulin bind-
ing to IR induces conformational changes in the CT domain
[21]. In addition, our model predicts that Ser/Thr phospho-
rylation may shift the equilibrium from A to B form, which is
consistent with previous observations that phorbol ester-
stimulated Ser/Thr phosphorylation results in the inhibition
of insulin-stimulated PTK activity [22^24]. Excessive Ser/Thr
phosphorylation of the IR has been proposed to be involved
in the decreased IR PTK activity observed in many insulin-
dependent diabetes patients with insulin resistance [25,26].
Finally, it is necessary to extend this in vitro structure-func-
tion study into a more physiological realm. Kole et al. very
recently reported the role of a synthetic peptide derived from
IR CT domain in the regulation of insulin signal transduction
[27]. The IR CT peptide corresponding to 1293^1307 stimu-
lated autophosphorylation of the IR L subunit, phosphatid-
ylinositol (PI) kinase activity, and MAP kinase activity in
CHO/HIRc cells in the presence of insulin. They also showed
that the IR CT peptide was speci¢cally cross-linked to IR and
IR lacking 43 amino acids from the carboxyl terminus of the
L subunit, but not to IGFIR or EGF receptor. These data
suggested that this peptide binds speci¢cally to the IR L sub-
unit in a region other than the carboxyl terminal 43 amino
acids. Their results are analogous to our ¢ndings including
that IR CT binds to PTK domain. In addition, we showed
that IR CT stimulates IR PTK activity whereas it does not
have an e¡ect on IGFIR PTK (Table 1). It is not known,
however, whether the lack of IGFIR PTK stimulation by
IR CT is due to the lack of binding between the two molecules
or binding without functional stimulation. The study by Kole
et al. [27] indicates that the latter may be correct. The major
¢nding of the present study is that IGFIR CT also interacts
with IR PTK and thereby stimulates its PTK activity.
Although our reconstitution experiments did not directly dem-
onstrate a possible physiological role, one can imagine that
this interaction may play a signi¢cant role in the IGFIR/IR
hybrid molecules which exist in cells expressing both receptors
[18,28^30]. As illustrated in Fig. 3, an intact IGFIR could
dimerize with an inactive CT-truncated IR. The IGFIR CT
domain then could interact with IR PTK, which could result
in the activation of IR PTK. Obviously, more experiments
will be needed to prove this hypothesis.
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